Choosing an Autoinjector for Patients With Severe Eosinophilic Asthma

<p>NUCALA (mepolizumab) is for the add-on treatment of patients 6+ with severe eosinophilic asthma. Not for acute bronchospasm or status asthmaticus.</p> <p><strong>Please See Important Safety Information Below</strong></p> <p>Every patient with severe eosinophilic asthma has different kinds of needs, which is why it's important to have a treatment available that has options. With the NUCALA Autoinjector, clinicians have the power to choose at-home or in-office administration for appropriate patients aged 12 years and older. Could NUCALA make a difference for your patients?</p> <p style="text-align: right;"><span>MPLWCNT210112 October 2021<br /></span>Produced in USA.</p>